Interferon-gamma (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell Transplantation
Phase 2
45
about 3.1 years
18+
3 sites in MO, PA, WA
What this study is about
This trial is testing a treatment with donor leukocytes and interferon gamma for patients whose leukemia or myelodysplastic syndromes have returned after a stem cell transplant. The goal is to see if these treatments can help the leukemia cells respond to interferon gamma, using techniques like single-cell RNA sequencing to understand how the treatments affect the leukemia cells.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive Donor Leukocyte Infusion (DLI)
- 2.Take Interferon gamma-1b
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Immunological Agents (Biological Response Modifiers)
infusion, injection (Injection)
Primary: Event-free survival (EFS)
Secondary: Complete Remission (CR), Event-free survival (EFS) - Landmark 1-year, Frequency and severity of adverse events (AEs), Minimal residual disease (MRD), Overall survival
Oncology